Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Lazorchak

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Trends in Immunology|June 1, 2005
New insights into E-protein function in lymphocyte developmentAdam Lazorchak, Mary Elizabeth Jones, Yuan Zhuang
The EMBO Journal|June 21, 2008
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase CValeria Facchinetti, Weiming Ouyang, Hua Wei, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 7, 2025
A Precision Gene Engineered B Cell Medicine Producing Sustained Levels of Active Factor IX for Hemophilia B TherapyHanlan Liu, Swati Singh, Timothy J Mullen, et al.
Journal for Immunotherapy of Cancer|July 20, 2022
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responsesYan Lan, Tsz-Lun Yeung, Hui Huang, et al.
Cancer Cell|September 10, 2021
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasionYan Lan, Mahmoud Moustafa, Maximilian Knoll, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Trends in Immunology|June 1, 2005
New insights into E-protein function in lymphocyte developmentAdam Lazorchak, Mary Elizabeth Jones, Yuan Zhuang
The EMBO Journal|June 21, 2008
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase CValeria Facchinetti, Weiming Ouyang, Hua Wei, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 7, 2025
A Precision Gene Engineered B Cell Medicine Producing Sustained Levels of Active Factor IX for Hemophilia B TherapyHanlan Liu, Swati Singh, Timothy J Mullen, et al.
Journal for Immunotherapy of Cancer|July 20, 2022
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responsesYan Lan, Tsz-Lun Yeung, Hui Huang, et al.
Cancer Cell|September 10, 2021
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasionYan Lan, Mahmoud Moustafa, Maximilian Knoll, et al.
Pageof 1